Nonbiological pharmacotherapies for the treatment of diabetic macular edema.

about

Chrysin Ameliorates Malfunction of Retinoid Visual Cycle through Blocking Activation of AGE-RAGE-ER Stress in Glucose-Stimulated Retinal Pigment Epithelial Cells and Diabetic Eyes

P2860

Q58795147-C202FE74-321D-47AA-BDAD-CD949D32D244

P2860

Nonbiological pharmacotherapies for the treatment of diabetic macular edema.

Item

http://www.wikidata.org/entity/Q38622256

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh

2015年學術文章

@zh-hant

name

Nonbiological pharmacotherapies for the treatment of diabetic macular edema.

@en

type

Item

label

Nonbiological pharmacotherapies for the treatment of diabetic macular edema.

@en

prefLabel

Nonbiological pharmacotherapies for the treatment of diabetic macular edema.

@en

P1476

Nonbiological pharmacotherapies for the treatment of diabetic macular edema.

@en

P2093

Aniruddha Agarwal

http://www.w3.org/2001/XMLSchema#string

Colby Argo

http://www.w3.org/2001/XMLSchema#string

Diana V Do

http://www.w3.org/2001/XMLSchema#string

Jacob Parriott

http://www.w3.org/2001/XMLSchema#string

Quan Dong Nguyen

http://www.w3.org/2001/XMLSchema#string

Sibel Demirel

http://www.w3.org/2001/XMLSchema#string

Yasir Jamal Sepah

http://www.w3.org/2001/XMLSchema#string

P2860

Topical non-steroidal anti-inflammatory agents for diabetic cystoid macular oedema

Industrialization of mAb production technology: the bioprocessing industry at a crossroads

A review of therapies for diabetic macular oedema and rationale for combination therapy

Danazol--a synthetic steroid derivative with interesting physiologic properties

Vascular adhesion protein-1 regulates leukocyte transmigration rate in the retina during diabetes

Effect of ruboxistaurin on visual loss in patients with diabetic retinopathy.

Ocular permeation and inhibition of retinal inflammation: an examination of data and expert opinion on the clinical utility of nepafenac.

Intravitreal triamcinolone for refractory diabetic macular edema: two-year results of a double-masked, placebo-controlled, randomized clinical trial.

A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema.

Sustained ocular delivery of fluocinolone acetonide by an intravitreal insert.

P304

2625-2635

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/14656566.2015.1100172

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-11-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

283457049

http://www.w3.org/2001/XMLSchema#string

P698

26523670

http://www.w3.org/2001/XMLSchema#string

P921

pharmacotherapy

Nonbiological pharmacotherapies for the treatment of diabetic macular edema.

about

P2860

P2860

Nonbiological pharmacotherapies for the treatment of diabetic macular edema.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P5875

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P5875

P698

P921